SG11201608566UA - New markers for the assessment of an increased risk for mortality - Google Patents
New markers for the assessment of an increased risk for mortalityInfo
- Publication number
- SG11201608566UA SG11201608566UA SG11201608566UA SG11201608566UA SG11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA
- Authority
- SG
- Singapore
- Prior art keywords
- mortality
- assessment
- increased risk
- new markers
- markers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305856 | 2014-06-05 | ||
| EP14306530 | 2014-09-30 | ||
| PCT/EP2015/062460 WO2015185672A2 (en) | 2014-06-05 | 2015-06-03 | New markers for the assessment of an increased risk for mortality |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608566UA true SG11201608566UA (en) | 2016-11-29 |
Family
ID=53385620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608566UA SG11201608566UA (en) | 2014-06-05 | 2015-06-03 | New markers for the assessment of an increased risk for mortality |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170102396A1 (en) |
| EP (2) | EP3152580B1 (en) |
| CN (1) | CN107076756B (en) |
| CA (1) | CA2949731A1 (en) |
| IL (1) | IL249322A0 (en) |
| SG (1) | SG11201608566UA (en) |
| WO (1) | WO2015185672A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015140317A1 (en) * | 2014-03-21 | 2015-09-24 | Sanofi | New markers for the assessment of the risk for development of a cardiovascular disorder |
| JP6622102B2 (en) * | 2016-02-04 | 2019-12-18 | 松森 昭 | Determination method of acute myocardial infarction |
| WO2019081504A1 (en) | 2017-10-24 | 2019-05-02 | Sphingotec Gmbh | Selenoprotein p for prediction of a first cardiovascular event |
| WO2019115620A1 (en) | 2017-12-13 | 2019-06-20 | Roche Diagnostics Gmbh | Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke |
| US20220043005A1 (en) | 2018-12-20 | 2022-02-10 | Sphingotec Gmbh | Selenoprotein p in heart failure |
| CN112180093B (en) * | 2019-07-02 | 2024-03-08 | 复旦大学附属华山医院 | Critical disease mortality diagnostic biomarker tenascin-c and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
| WO2010012616A1 (en) * | 2008-07-30 | 2010-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure |
| CA2736722A1 (en) * | 2008-09-11 | 2010-03-18 | F.Hoffmann-La Roche Ag | Natriuretic peptides and adiponectin in subjects with a metabolic syndrome |
| KR20140051754A (en) * | 2010-02-26 | 2014-05-02 | 아스튜트 메디컬 인코포레이티드 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2012094580A2 (en) * | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Compounds that modulate oxidative stress |
| EP2761289B1 (en) * | 2011-09-30 | 2020-02-12 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| WO2013152047A1 (en) * | 2012-04-02 | 2013-10-10 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of sepsis |
| US9733261B2 (en) * | 2012-04-24 | 2017-08-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury |
| US20140072959A1 (en) * | 2012-09-12 | 2014-03-13 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
-
2015
- 2015-06-03 EP EP15728476.1A patent/EP3152580B1/en active Active
- 2015-06-03 CA CA2949731A patent/CA2949731A1/en not_active Abandoned
- 2015-06-03 SG SG11201608566UA patent/SG11201608566UA/en unknown
- 2015-06-03 WO PCT/EP2015/062460 patent/WO2015185672A2/en active Application Filing
- 2015-06-03 EP EP19199735.2A patent/EP3633382A1/en active Pending
- 2015-06-03 US US15/315,784 patent/US20170102396A1/en active Pending
- 2015-06-03 CN CN201580041834.XA patent/CN107076756B/en active Active
-
2016
- 2016-12-01 IL IL249322A patent/IL249322A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3152580A2 (en) | 2017-04-12 |
| EP3152580B1 (en) | 2019-10-16 |
| US20170102396A1 (en) | 2017-04-13 |
| EP3633382A1 (en) | 2020-04-08 |
| CA2949731A1 (en) | 2015-12-10 |
| CN107076756B (en) | 2019-08-16 |
| CN107076756A (en) | 2017-08-18 |
| WO2015185672A3 (en) | 2016-02-25 |
| WO2015185672A2 (en) | 2015-12-10 |
| IL249322A0 (en) | 2017-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2512543B (en) | Object tracking | |
| HUE055211T2 (en) | An equipment with side-shifter | |
| SG11201610690VA (en) | Ethylene-based polymers | |
| GB201407680D0 (en) | Indicator | |
| IL246499A0 (en) | Epicutaneous immunorebalancing | |
| GB2528233B (en) | Identifying features | |
| IL249322A0 (en) | New markers for the assessment of an increased risk for mortality | |
| HK1242947A1 (en) | Spring-ejected biopsy marker | |
| GB201417553D0 (en) | Embryo Assessment | |
| SG11201606346TA (en) | Intermittent-bubbling equipment | |
| IL247366A0 (en) | Inhibitors of the wnt signalling pathways | |
| GB2533151B (en) | Improved probe | |
| PT3151658T (en) | Horseshoe | |
| GB201504086D0 (en) | Life jacket attachment | |
| GB201409620D0 (en) | Range determination | |
| GB201518601D0 (en) | Equipment calibration | |
| SG11201701736TA (en) | Thermal-history-change-type indicator | |
| GB201401005D0 (en) | Inhibitor | |
| SG11201702732UA (en) | Oxidant-dependent time indicator | |
| GB201414306D0 (en) | Test target | |
| GB201417275D0 (en) | Tripod Portion | |
| TWM490643U (en) | Transformer | |
| GB201406771D0 (en) | Assessment system | |
| GB201712443D0 (en) | Markers | |
| GB201619771D0 (en) | Indicator |